Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease - PubMed (original) (raw)

. 2003 Jun 15;167(12):1687-94.

doi: 10.1164/rccm.200208-905OC. Epub 2003 Feb 20.

Affiliations

• PMID: 12615624
• DOI: 10.1164/rccm.200208-905OC

Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease

Hajime Fujimoto et al. Am J Respir Crit Care Med. 2003.

Abstract

Intraalveolar activation of the coagulation system due to reduced fibrinolytic function plays a critical role in the pathogenesis of interstitial lung disease. Recently, a new potent inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor, has been isolated and characterized from human plasma. This study evaluated the levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor, another suppressor of fibrinolysis, in the bronchoalveolar lavage fluid from patients with interstitial lung disease. There were 82 patients with interstitial lung disease and 8 normal subjects. The bronchoalveolar lavage fluid levels of thrombin-activatable fibrinolysis inhibitor and protein C inhibitor were significantly higher in all patients with interstitial lung disease than in normal subjects. Both inhibitors of fibrinolysis were significantly and inversely correlated with fibrinolytic activity in all patients. The levels of thrombin-activatable fibrinolysis inhibitor were significantly correlated with those of protein C inhibitor, thrombin-antithrombin complex, and monocyte chemoattractant protein-1. Reverse transcriptase-polymerase chain reaction showed that alveolar macrophages isolated from patients with interstitial lung disease as well as immortalized lung epithelial cell lines express thrombin-activatable fibrinolysis inhibitor antigen. Overall, these findings suggest that thrombin-activatable fibrinolysis inhibitor and protein C inhibitor may play important roles in the mechanism of intraalveolar hypofibrinolysis associated with interstitial lung diseases.

PubMed Disclaimer

Comment in

• To clot or not to clot, that is the question in pulmonary fibrosis.
  Strieter RM. Strieter RM. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1589-90. doi: 10.1164/rccm.2303007. Am J Respir Crit Care Med. 2003. PMID: 12796052 Review. No abstract available.

Similar articles

• Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
  Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y. Hataji O, et al. Am J Hematol. 2004 Jul;76(3):214-9. doi: 10.1002/ajh.20079. Am J Hematol. 2004. PMID: 15224354
• Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
  Maris NA, de Vos AF, Bresser P, van der Zee JS, Jansen HM, Levi M, van der Poll T. Maris NA, et al. Crit Care Med. 2007 Jan;35(1):57-63. doi: 10.1097/01.CCM.0000249827.29387.4E. Crit Care Med. 2007. PMID: 17080003 Clinical Trial.
• Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.
  Fujimoto H, Gabazza EC, Taguchi O, Nishii Y, Nakahara H, Bruno NE, D'Alessandro-Gabazza CN, Kasper M, Yano Y, Nagashima M, Morser J, Broze GJ, Suzuki K, Adachi Y. Fujimoto H, et al. Am J Pathol. 2006 Apr;168(4):1086-96. doi: 10.2353/ajpath.2006.050610. Am J Pathol. 2006. PMID: 16565485 Free PMC article.
• [Role of alveolar macrophages in the pathogenesis of idiopathic interstitial pneumonia].
  Suga M, Iyonaga K, Ando M. Suga M, et al. Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Dec;34 Suppl:175-80. Nihon Kyobu Shikkan Gakkai Zasshi. 1996. PMID: 9216211 Review. Japanese.
• [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
  Stasko J, Hudecek J, Kubisz P. Stasko J, et al. Vnitr Lek. 2004 Jan;50(1):36-44. Vnitr Lek. 2004. PMID: 15015228 Review. Slovak.

Cited by

• Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
  Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA. Slofstra SH, et al. Br J Pharmacol. 2006 Nov;149(6):740-6. doi: 10.1038/sj.bjp.0706915. Epub 2006 Oct 3. Br J Pharmacol. 2006. PMID: 17016502 Free PMC article.
• The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.
  Kelly-Robinson GA, Reihill JA, Lundy FT, McGarvey LP, Lockhart JC, Litherland GJ, Thornbury KD, Martin SL. Kelly-Robinson GA, et al. Int J Mol Sci. 2021 Jun 14;22(12):6351. doi: 10.3390/ijms22126351. Int J Mol Sci. 2021. PMID: 34198546 Free PMC article. Review.
• Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
  Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F. Fidan E, et al. Tumour Biol. 2012 Oct;33(5):1519-25. doi: 10.1007/s13277-012-0403-6. Epub 2012 Apr 27. Tumour Biol. 2012. PMID: 22535370
• Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.
  Eser M, Kement M, Balin S, Coskun C, Kefeli U, Gumus M, Altuntas YE, Kurt N, Mayadagli A. Eser M, et al. World J Surg Oncol. 2012 Aug 31;10:180. doi: 10.1186/1477-7819-10-180. World J Surg Oncol. 2012. PMID: 22938027 Free PMC article.
• Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome.
  Heslet L, Andersen JS, Sengeløv H, Dahlbäck B, Dalsgaard-Nielsen J. Heslet L, et al. Biologics. 2007 Dec;1(4):465-72. Biologics. 2007. PMID: 19707316 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program
  • National BioResource Project